Fulfilling Potential In the Treatment of Gastrointestinal and Rare Diseases

Alcresta Therapeutics is a company dedicated to developing and commercializing novel enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency, which results in malabsorption common in cystic fibrosis, digestive cancers, premature birth and other serious diseases. The company’s lead product, RELiZORB™, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral tube feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). The importance of long-chain polyunsaturated fatty acids like omega-3 is well documented across the full spectrum of patient care from infants to adults and individuals battling acute conditions or chronic diseases.

Year Invested: 2011
Location: Newton, Mass.
Visit: www.alcresta.com

Recent News

January 3, 2019
Alcresta Therapeutics Announces that RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a Permanent Medicare Billing Code (B4105) by the Centers for Medicare and Medicaid Services (CMS)

August 2, 2018
Data from the ASSURE Study of Long-Term Use of RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE Published in Journal of Pediatric Gastroenterology and Nutrition

June 18, 2018
Alcresta Therapeutics Announces RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE has been Issued a Unique Q-Code (Q9994) by CMS

Read More News

Associated Team Members

Robert Tepper, M.D.

Kevin Gillis
Partner/Chief Operating Officer